Kyle Gano - 01 Nov 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role: Chief Executive Officer, Director
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol: NBIX
Transactions as of: 01 Nov 2025
Transactions value $: -$42,591
Form type: 4
Filing time: 04 Nov 2025, 20:18:14 UTC
Previous filing: 14 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gano Kyle	Chief Executive Officer, Director	6027 EDGEWOOD BEND CT., SAN DIEGO	/s/ Darin Lippoldt, Attorney-in-Fact	04 Nov 2025	0001567160

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NBIX	Common Stock	Options Exercise	$0	+613	+0.44%	$0.00	141K	01 Nov 2025	Direct	F1
transaction	NBIX	Common Stock	Sale	-$42.6K	-300	-0.21%	$141.97	140K	04 Nov 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBIX	Restricted Stock Unit	Options Exercise	$0	-613	-24.97%	$0.00	1.84K	01 Nov 2025	Common Stock	613		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F2	The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F3	Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
F4	This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on November 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.